Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

por Brasso C, Bellino S, Bozzatello P, Montemagni C, Rocca P
Publicado 2017

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase II...

por Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Publicado 2017